Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Sollinger

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Advances in Renal Replacement Therapy|April 1, 1994
Renal replacement therapy in diabetic nephropathyS W Zimmerman, H Sollinger, M Wakeen, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 9, 2010
Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantationN Neidlinger, N Singh, C Klein, et al.
Human Immunology|December 1, 1996
Expression of human recombinant beta 2-microglobulin by Aspergillus nidulans and its activityS M O'Herrin, S Kulkarni, W R Kenealy, et al.
Clinical Nephrology|August 31, 2006
Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patientsM Salvadori, H Holzer, G Civati, et al.
Journal of Inherited Metabolic Disease|November 20, 1998
Renal transplantation in a patient with methylmalonic acidaemiaS C Van Calcar, C O Harding, P Lyne, et al.
Transplantation|January 27, 1996
A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantationR W Gruessner, G W Burke, R Stratta, et al.
Clinical Transplantation|June 1, 2000
Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokineticsM D Pescovitz, D Conti, J Dunn, et al.
Transplantation|September 15, 1996
A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study GroupE S Woodle, J R Thistlethwaite, J H Gordon, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Advances in Renal Replacement Therapy|April 1, 1994
Renal replacement therapy in diabetic nephropathyS W Zimmerman, H Sollinger, M Wakeen, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 9, 2010
Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantationN Neidlinger, N Singh, C Klein, et al.
Human Immunology|December 1, 1996
Expression of human recombinant beta 2-microglobulin by Aspergillus nidulans and its activityS M O'Herrin, S Kulkarni, W R Kenealy, et al.
Clinical Nephrology|August 31, 2006
Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patientsM Salvadori, H Holzer, G Civati, et al.
Journal of Inherited Metabolic Disease|November 20, 1998
Renal transplantation in a patient with methylmalonic acidaemiaS C Van Calcar, C O Harding, P Lyne, et al.
Transplantation|January 27, 1996
A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantationR W Gruessner, G W Burke, R Stratta, et al.
Clinical Transplantation|June 1, 2000
Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokineticsM D Pescovitz, D Conti, J Dunn, et al.
Transplantation|September 15, 1996
A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study GroupE S Woodle, J R Thistlethwaite, J H Gordon, et al.
Pageof 2